Roche acquires Telavant Holdings for USD 7.1 billion Ruchika Sharma24 Oct 2023 12:30 PM ISTBasel: Roche has announced the entry into a definitive agreement to acquire Telavant Holdings, Inc., a Roivant company, owned by Roivant Sciences Ltd....
Eli Lilly Mirikizumab helps patients with Crohn's Disease achieve long-term Remission in Phase 3 trial Ruchika Sharma15 Oct 2023 12:30 PM ISTIndianapolis: Eli Lilly and Company has announced that mirikizumab (an investigational interleukin-23p19 antagonist) has met the co-primary...
Sanofi-Teva Pharma to co-develop, co-commercialize inflammatory bowel disease treatment Ruchika Sharma5 Oct 2023 2:30 PM ISTParis: Sanofi and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. have announced a collaboration to co-develop and...
Takeda gets USFDA nod for subcutaneous administration of Entyvio for ulcerative colitis Ruchika Sharma29 Sept 2023 12:30 PM ISTOsaka: Takeda has announced that the U.S. Food and Drug Administration (FDA) has approved a subcutaneous (SC) administration of ENTYVIO...
USFDA accepts BLA for subcutaneous administration of Takeda Entyvio for maintenance therapy in Crohn's Disease Ruchika Sharma14 Sept 2023 3:58 PM ISTOsaka: Takeda today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its Biologics License Application (BLA)...
Sandoz bags USFDA approval for biosimilar Tyruko for relapsing forms of multiple sclerosis Ruchika Sharma26 Aug 2023 11:00 AM ISTTyruko has the same intravenous dosage form, route of administration, dosing regimen and presentation as the reference medicine.
Gut Microbiome Composition associated with future onset of Crohn's Disease in Healthy First-Degree Relatives Dr. Shravani Dali4 Jun 2023 8:00 PM ISTGut Microbiome Composition is associated with future onset of Crohn's Disease in Healthy First-Degree Relatives suggests a new study published in the...
AstraZeneca discontinues brazikumab inflammatory bowel disease development programme Ruchika Sharma2 Jun 2023 1:30 PM ISTCambridge: AstraZeneca has announced the discontinuation of the brazikumab inflammatory bowel disease (IBD) development programme, an anti-IL-23...
FDA approves Upadacitinib for Crohn's disease in adults Dr. Kamal Kant Kohli19 May 2023 10:00 AM ISTThe U.S. Food and Drug Administration (FDA) has approved Upadacitinib for treatment of adults with moderately to severely active Crohn's disease...
Melatonin use may impair action of gut microbiota and worsen IBD Dr. Kamal Kant Kohli10 May 2023 8:00 PM ISTBrazil: Melatonin can worsen the inflammation of the intestine and impair the action of gut microbiota despite its antioxidant effects and role in...
Fecal microbiota transplantation more effective than antibiotics for treating recurrent C difficile infection Dr. Kamal Kant Kohli1 May 2023 8:15 PM ISTUSA: A new Cochrane Review showed a large increase in the resolution of recurrent Clostridioides difficile infection with stool transplantation...
J&J Gets CDSCO Panel Nod To Conduct Phase IV CT of Ustekinumab Dr. Divya Colin16 April 2023 5:45 PM ISTNew Delhi: In order to evaluate safety of Ustekinumab in Indian subjects with Crohn’s Disease (CD), pharmaceutical major, Johnson & Johnson has...
